Suppr超能文献

以性别为关键预测因素的脑转移瘤的低分割和单次分割放射外科治疗。

Hypofractionated and single-fraction radiosurgery for brain metastases with sex as a key predictor of overall survival.

机构信息

Department of Therapeutic Radiology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.

Department for Medical Statistics, Medical University of Innsbruck, Innsbruck, Austria.

出版信息

Sci Rep. 2021 Apr 21;11(1):8639. doi: 10.1038/s41598-021-88070-5.

Abstract

Overall survival (OS) of patients with brain metastases treated with hypofractionated (HFSRT) or single-fraction (SRS) radiosurgery depends on several prognostic factors. The aim of this study was to investigate the potential of sex as an independent predictor of OS and evaluate the predictive accuracy of common prognostic scores. Retrospective analysis of 281 consecutive patients receiving radiosurgery of brain metastases was performed. Kaplan-Meier survival curves and Cox proportional hazards models were used to compare OS between SRS and HFSRT and by sex, before and after propensity-score matching (PSM) on key baseline prognostic covariates. Prognostic scores were evaluated using Harrell's concordance index. Median OS was 11 months after both SRS and HFSRT. After PSM, median OS was 12 months after SRS (95% CI: 7.5-16.5) and 9 months after HFSRT (95% CI: 5.0-13.0; p = 0.77). Independent prognostic factors were sex, primary tumor, KPI, and systemic disease status. Median OS was 16 months for women and 7 months for male patients (p < 0.001). After excluding sex specific tumors, PSM revealed a median OS of 16 months for women and 8 months for male patients (p < 0.01). Evaluation of prognostic indices showed BSBM to be the most accurate (Harrell's C = 0.68), followed by SIR (0.61), GPA (0.60), RPA (0.58), and Rades et al. (0.57). OS after HFSRT and SRS did not differ, although PSM revealed a non-significant advantage for SRS. Female sex was found to be a major independent positive prognostic factor for survival, and thus should be considered in the personalized decision-making of brain metastases treatment.

摘要

脑转移瘤患者接受立体定向放射外科治疗(SRS)或大分割立体定向放射治疗(HFSRT)后的总生存(OS)取决于多个预后因素。本研究旨在探讨性别是否为 OS 的独立预测因素,并评估常见预后评分的预测准确性。对 281 例连续接受脑转移瘤放射外科治疗的患者进行回顾性分析。使用 Kaplan-Meier 生存曲线和 Cox 比例风险模型比较 SRS 和 HFSRT 之间以及按性别比较 OS,在对关键基线预后协变量进行倾向评分匹配(PSM)之前和之后。使用 Harrell 的一致性指数评估预后评分。SRS 和 HFSRT 后中位 OS 分别为 11 个月和 9 个月。PSM 后,SRS 后中位 OS 为 12 个月(95%CI:7.5-16.5),HFSRT 后为 9 个月(95%CI:5.0-13.0;p = 0.77)。独立的预后因素为性别、原发肿瘤、KPI 和全身疾病状态。女性患者的中位 OS 为 16 个月,男性患者为 7 个月(p<0.001)。排除性别特异性肿瘤后,PSM 显示女性患者的中位 OS 为 16 个月,男性患者为 8 个月(p<0.01)。对预后指数的评估显示 BSBM 最准确(Harrell 的 C=0.68),其次是 SIR(0.61)、GPA(0.60)、RPA(0.58)和 Rades 等人(0.57)。HFSRT 和 SRS 后的 OS 没有差异,尽管 PSM 显示 SRS 有非显著性优势。女性被发现是生存的一个主要独立的正预后因素,因此在脑转移瘤治疗的个体化决策中应考虑到这一点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4ac/8060341/e7a3556d4029/41598_2021_88070_Fig1_HTML.jpg

相似文献

2
Comparison of prognostic indices in patients who undergo melanoma brain metastasis radiosurgery.
J Neurosurg. 2018 Jan;128(1):14-22. doi: 10.3171/2016.9.JNS161011. Epub 2017 Jan 20.
3
4
Brain metastases treated with radiosurgery or hypofractionated stereotactic radiotherapy: outcomes and predictors of survival.
Clin Transl Oncol. 2020 Oct;22(10):1809-1817. doi: 10.1007/s12094-020-02321-x. Epub 2020 Mar 2.
6
7
Prognostic factors for melanoma brain metastases treated with stereotactic radiosurgery.
J Neurosurg. 2016 Dec;125(Suppl 1):31-39. doi: 10.3171/2016.8.GKS161359.
8
Single-fraction radiosurgery versus fractionated stereotactic radiotherapy in patients with brain metastases: a comparative study.
Clin Exp Metastasis. 2020 Jun;37(3):425-434. doi: 10.1007/s10585-020-10031-5. Epub 2020 Mar 17.

引用本文的文献

2
Sex-specific difference in treatment success/failure after vestibular schwannoma treatment.
Neurooncol Adv. 2025 Jan 29;7(1):vdaf025. doi: 10.1093/noajnl/vdaf025. eCollection 2025 Jan-Dec.
5
Gender oncology: recommendations and consensus of the Italian Association of Medical Oncology (AIOM).
ESMO Open. 2024 Feb;9(2):102243. doi: 10.1016/j.esmoop.2024.102243. Epub 2024 Feb 23.
6
Refining accuracy of RV-PA coupling in patients undergoing transcatheter tricuspid valve treatment.
Clin Res Cardiol. 2024 Jan;113(1):177-186. doi: 10.1007/s00392-023-02339-5. Epub 2023 Nov 27.
8
Midlife brain metastases in the United States: Is male at risk?
Cancer Med. 2022 Feb;11(4):1202-1216. doi: 10.1002/cam4.4499. Epub 2022 Jan 12.

本文引用的文献

1
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy.
Molecules. 2019 Sep 4;24(18):3214. doi: 10.3390/molecules24183214.
2
The METABANK score: A clinical tool to predict survival after stereotactic radiotherapy for oligometastatic disease.
Radiother Oncol. 2019 Apr;133:113-119. doi: 10.1016/j.radonc.2019.01.001. Epub 2019 Jan 24.
3
Sex Differences in Cancer: Epidemiology, Genetics and Therapy.
Biomol Ther (Seoul). 2018 Jul 1;26(4):335-342. doi: 10.4062/biomolther.2018.103.
4
Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?
ESMO Open. 2018 Apr 13;3(3):e000344. doi: 10.1136/esmoopen-2018-000344. eCollection 2018.
6
Clinical outcomes of patients with limited brain metastases treated with hypofractionated (5×6Gy) conformal radiotherapy.
Radiother Oncol. 2017 May;123(2):203-208. doi: 10.1016/j.radonc.2017.03.018. Epub 2017 Apr 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验